Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Complications

The Early Natural History of Nephropathy in Type 1 Diabetes

I. Study Design and Baseline Characteristics of the Study Participants

  1. Michael Mauer1,
  2. Keith Drummond2 and
  3. for the International Diabetic Nephropathy Study Group
  1. 1Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota
  2. 2Department of Pediatrics, McGill University, Montreal, Canada
    Diabetes 2002 May; 51(5): 1572-1579. https://doi.org/10.2337/diabetes.51.5.1572
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    I. Study Design and Baseline Characteristics of the Study Participants

    Abstract

    This report describes the design and baseline demographic and clinical data in the study of the early natural history of diabetic nephropathy (DN) in type 1 diabetes carried out by the International Diabetic Nephropathy Study Group. The study enrolled 243 patients ages 10–40 years (16.8 ± 6.0, mean ± SD) with type 1 diabetes for 2–20 years (8.0 ± 4.2) at centers in the United States (Minneapolis), Canada (Montreal), and France (Paris). At baseline, all patients were normotensive, none had reduced glomerular filtration rate (GFR), and all but eight were normoalbuminuric (NA). All patients had baseline renal biopsies. During the study, patients will have multiple measurements of blood pressure (BP), renal function, albumin excretion rate (AER), glycemia, and other variables, with repeat renal biopsies planned at 5 years after baseline. The 31.3% of the approached patients who agreed to participate were similar in age, diabetes duration, HbA1c, AER, and sex to those refusing participation. Age, diabetes duration, HbA1c, and AER were similar among the three centers, but systolic BP, GFR, renal plasma flow (RPF), and filtration fraction were lower in the Paris center. The 153 patients with hyperfiltration (GFR >130 ml · min−1 · 1.73 m−2) had greater RPF than those with normal GFR. The eight microalbuminuric patients tended to have longer duration of diabetes but were otherwise similar to the NA patients. The role of these and other variables in determining the development rate of the early lesions of DN over the 5 years between biopsies is the central issue under study.

    Footnotes

    • The members of the International Diabetic Nephropathy Study Group are listed in the appendix.

      Address correspondence and reprint requests to Michael Mauer, Department of Pediatrics, University of Minnesota, MMC491, 420 Delaware St. S.E., Minneapolis MN 55455. E-mail: mauer002{at}tc.umn.edu.

      See companion article on p. 1580.

      Received for publication 26 July 2001 and accepted in revised form 8 February 2002.

      AER, albumin excretion rate; AP, adjusted parameter; BP, blood pressure; CV, coefficient of variation; DBP, diastolic blood pressure; DN, diabetic nephropathy; ESRD, end-stage renal disease; FF, filtration fraction; GFR, glomerular filtration rate; HPLC, high-performance liquid chromatography; IDNSG, International Diabetic Nephropathy Study Group; MA, microalbuminuric; NA, normoalbuminuric; PAH, para-amino hippurate; RBF, renal blood flow; SBP, systolic blood pressure; UUN, urinary urea nitrogen; Vv(Mes/glom), fractional mesangial volume.

    • DIABETES
    View Full Text
    PreviousNext
    Back to top

    In this Issue

    May 2002, 51(5)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    The Early Natural History of Nephropathy in Type 1 Diabetes
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    The Early Natural History of Nephropathy in Type 1 Diabetes
    Michael Mauer, Keith Drummond
    Diabetes May 2002, 51 (5) 1572-1579; DOI: 10.2337/diabetes.51.5.1572

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    The Early Natural History of Nephropathy in Type 1 Diabetes
    Michael Mauer, Keith Drummond
    Diabetes May 2002, 51 (5) 1572-1579; DOI: 10.2337/diabetes.51.5.1572
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • APPENDIX
      • Acknowledgments
      • Footnotes
      • References
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Interphotoreceptor Retinol-Binding Protein Ameliorates Diabetes-Induced Retinal Dysfunction and Neurodegeneration Through Rhodopsin
    • Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker–Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19
    • Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis
    Show more Complications

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.